FDA Advisory Committee Votes in Favor of XELJANZ® (tofacitinib citrate) for the Treatment of Active Psoriatic Arthritis

97

​Pfizer Inc. announced today that the United States Food and Drug Administration’s (FDA) Arthritis Advisory Committee (AAC) voted 10 to 1 to recommend approval . . .

http://www.pfizer.com/news/press-release/press-release-detail/fda_advisory_committee_votes_in_favor_of_xeljanz_tofacitinib_citrate_for_the_treatment_of_active_psoriatic_arthritis